What is the impact of anemia pharmacotherapy on chronic kidney disease progression?

被引：0
作者：
Webb, Hanna T. [1 ]
Wish, Jay B. [1 ]
机构：
[1] Indiana Univ Sch Med, Div Nephrol, Indianapolis, IN USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2024年 / 25卷 / 10期
关键词：
Anemia; chronic kidney disease; erythropoietin; hypoxia-inducible factor; SGLT2-inhibotors; CHRONIC-RENAL-FAILURE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; THERAPY; DECLINE; ALPHA;
D O I：
10.1080/14656566.2024.2384560
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1265 / 1269
页数：5
相关论文
共 17 条
  • [1] Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD
    Chertow, Glenn M.
    Pergola, Pablo E.
    Farag, Youssef M. K.
    Agarwal, Rajiv
    Arnold, Susan
    Bako, Gabriel
    Block, Geoffrey A.
    Burke, Steven
    Castillo, Fausto P.
    Jardine, Alan G.
    Khawaja, Zeeshan
    Koury, Mark J.
    Lewis, Eldrin F.
    Lin, Tim
    Luo, Wenli
    Maroni, Bradley J.
    Matsushita, Kunihiro
    McCullough, Peter A.
    Parfrey, Patrick S.
    Roy-Chaudhury, Prabir
    Sarnak, Mark J.
    Sharma, Amit
    Spinowitz, Bruce
    Tseng, Carol
    Tumlin, James
    Vargo, Dennis L.
    Walters, Kimberly A.
    Winkelmayer, Wolfgang C.
    Wittes, Janet
    Eckardt, Kai-Uwe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (17) : 1589 - 1600
  • [2] Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease
    Dean, BB
    Dylan, M
    Gano, A
    Knight, K
    Ofman, JJ
    Levine, BS
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 981 - 987
  • [3] Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Drueke, Tilman B.
    Locatelli, Francesco
    Clyne, Naomi
    Eckardt, Kai-Uwe
    Macdougall, Iain C.
    Tsakiris, Dimitrios
    Burger, Hans-Ulrich
    Scherhag, Armin
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) : 2071 - 2084
  • [4] Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial
    Gouva, C
    Nikolopoulos, P
    Ioannidis, JPA
    Siamopoulos, KC
    [J]. KIDNEY INTERNATIONAL, 2004, 66 (02) : 753 - 760
  • [5] Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates
    Habas Sr, Elmukhtar
    Al Adab, Aisha
    Arryes, Mehdi
    Alfitori, Gamal
    Farfar, Khalifa
    Habas, Ala M.
    Akbar, Raza A.
    Rayani, Amnna
    Habas, Eshrak
    Elzouki, Abdulnaser
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [6] Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
    Hayashi, Terumasa
    Maruyama, Shoichi
    Nangaku, Masaomi
    Narita, Ichiei
    Hirakata, Hideki
    Tanabe, Kenichiro
    Morita, Satoshi
    Tsubakihara, Yoshiharu
    Imai, Enyu
    Akizawa, Tadao
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (05): : 608 - 615
  • [7] Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
    Jungers, P
    Choukroun, G
    Oualim, Z
    Robino, C
    Nguyen, AT
    Man, NK
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (02) : 307 - 312
  • [8] Koshino Akihiko, 2023, NEJM Evid, V2, pEVIDoa2300049, DOI 10.1056/EVIDoa2300049
  • [9] Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
    Kuriyama, S
    Tomonari, H
    Yoshida, H
    Hashimoto, T
    Kawaguchi, Y
    Sakai, O
    [J]. NEPHRON, 1997, 77 (02): : 176 - 185
  • [10] LONG-TERM CARDIORESPIRATORY EFFECTS OF AMELIORATION OF RENAL ANEMIA BY ERYTHROPOIETIN
    MACDOUGALL, IC
    LEWIS, NP
    SAUNDERS, MJ
    COCHLIN, DL
    DAVIES, ME
    HUTTON, RD
    FOX, KAA
    COLES, GA
    WILLIAMS, JD
    [J]. LANCET, 1990, 335 (8688) : 489 - 493
12